Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

ONCT-534 interacts with both the N-terminal domain and the ligand-binding domain of the androgen receptor, inhibiting cell growth and inducing androgen receptor degradation.